甲胎蛋白衍生肽诱导的高亲和力T细胞受体与肝细胞癌患者抗肿瘤效应之间的关联
这项在日本金泽大学医院开展的1期前瞻性研究纳入15例晚期肝细胞癌患者,每两周皮下注射3 mg甲胎蛋白衍生肽(AFP357和AFP403)与不完全弗氏佐剂乳剂至少6周。未观察到严重不良反应,5例(33%)产生免疫应答,1例完全缓解,8例疾病稳定;完全缓解患者表达高亲和力T细胞受体。
要点
- 15例晚期肝细胞癌患者接受AFP357和AFP403肽疫苗,未出现严重不良反应。
- 5例(33%)产生针对肽的免疫应答,1例完全缓解,8例疾病稳定。
- 完全缓解超过2年的患者中检测到亲和力最高的T细胞受体。
核心结论
- 在1期试验中,给15例肝细胞癌患者施用甲胎蛋白衍生肽未引起不良事件,并产生针对该肽的T细胞;1例患者完全缓解,8例患者肿瘤生长减缓。
- 完全缓解患者的T细胞表达由肽疫苗诱导的高功能T细胞受体。
研究设计与样本
- 在日本金泽大学医院于2010年3月至2012年3月开展的前瞻性研究,纳入15例肝细胞癌患者。
- 每例患者每两周皮下注射3 mg甲胎蛋白衍生肽(AFP357和AFP403)与不完全弗氏佐剂乳剂,至少6周。
- 每8周进行影像学评估,不良事件和毒性按常见不良事件术语标准分级。
- 停药标准包括不可接受的毒性以及按实体瘤疗效评价标准定义的疾病进展。
- 观察期为730天。
主要发现
- 15例接受至少3次注射的患者中,5例(33%)对肽产生免疫应答。
- 15例患者中1例完全缓解,8例疾病稳定。
- 15例患者中4例检测到AFP357特异性CD8 T细胞,克隆出14种对肽亲和力不同的T细胞受体。
- 完全缓解持续超过2年的患者中观察到亲和力最高的T细胞受体。
- 未观察到针对肽的严重不良反应,耐受性良好。
关键数值与推荐
- 完全缓解定义为所有肿瘤消失。
- 疾病稳定定义为肿瘤总直径保持在基线测量的>70%且<120%之间,且无新病灶。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Levels of α-fetoprotein (AFP) are measured for surveillance and diagnosis of hepatocellular carcinoma (HCC). We performed a phase 1 trial to evaluate the safety and efficacy of AFP-derived peptides as an anti-tumor vaccine for patients with advanced HCC, and characterized induction of AFP-specific T-cell receptors (TCRs). METHODS: We performed a prospective study of 15 patients with HCC seen at Kanazawa University Hospital in Japan from March 2010 through March 2012. Each patient was given a subcutaneous injection of 3 mg AFP-derived peptides (AFP357 and AFP403) in an emulsion with incomplete Freund's adjuvant every other week for at least 6 weeks. Patients were evaluated every 8 weeks by radiologic imaging; adverse events and toxicities were categorized and graded using the common terminology criteria for adverse events. Criteria for discontinuation included unacceptable toxicities and disease progression defined as progressive disease using the Response Evaluation Criteria In Solid Tumors criteria. Patients' immune responses were monitored using an interferon-gamma enzyme-linked immunospot assay. Peptide-specific TCRs were assessed using a rapid TCR cloning and evaluation system. The observation period was 730 days. A complete response was defined as the disappearance of all tumors; stable disease was defined as tumors whose total diameter remained between >70% and <120% of the baseline measurement, without new lesions. RESULTS: We did not observe any serious adverse reactions to the peptides, which were well tolerated. Of the 15 patients who received at least 3 injections, 5 (33%) had an immune response to the peptides. One of the 15 patients had a complete response and disease stabilized in 8 patients. In 4 of the 15 patients, we detected AFP357-specific CD8 T cells; we cloned 14 different TCRs with different avidities for the peptide. A TCR with the highest avidity was observed in the patient who achieved a complete response for more than 2 years. CONCLUSIONS: In a phase 1 trial, administration of AFP-derived peptides to 15 patients with HCC did not cause adverse events and produced T cells with receptors that reacted to the peptides; 1 patient had a complete response and tumor growth slowed in 8 patients. T cells from the patient with a complete response expressed a highly functional TCR induced by the peptide vaccines. UMIN-CTR no: UMIN000003514.
引用
- Nakagawa H, Mizukoshi E, Kobayashi E, et al. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma. Gastroenterology. 2017. PMID: 28188748. doi:10.1053/j.gastro.2017.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。